Pfizer, Inc. · NYSE:PFE
Pfizer — 33rd Annual J.P. Morgan Healthcare Conference (January 2015)
18 slides from Pfizer's conference presentation, Jan 13, 2015
Slide 1: JP Morgan Healthcare Conference: Advancing Differentiated High Value Products
JP Morgan Healthcare Conference Advancing Differentiated High Value Products Mikael Dolsten, M.D., Ph.D. President Worldwide R&D January 13, 2015
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation includes forward-looking statements about, among other things, development of Pfizer’s products and product candidates, including their potential benefits, expected clinical trial study starts and expected regulatory submissions and approvals that are s
Slide 3: Novel Launched Products with Unique Clinical Profiles
Novel Launched Products with Unique Clinical Profiles Recent Approvals Pfizer Pipeline As of November 6, 2014 214 Discovery Phase 1 Phase 2 Phase 3 Registration 86 Projects 35 22 23 6 Total 3
Slide 4: Delivering Novel & Differentiated Future Potential Products
Delivering Novel & Differentiated Future Potential Products Large, High Quality R&D Pipeline with Mix of NMEs and New Indications Oncology CVMed Vaccines Inflammation Neuroscience Rare Disease Biosimilars & Pain Ibrance® bococizumab Prevenar ® 13 Xeljanz ® LCM Neuro – rivipansel VOC trastuzumab (pal
Slide 5: Delivering Novel & Differentiated Future Potential Products
Delivering Novel & Differentiated Future Potential Products Over the Next 4 Years: > 20 Potential Ph II/III Registration Study Starts > 15 Potential Approvals Oncology CVMed Vaccines Inflammation Neuroscience Rare Disease Biosimilars & Pain Ibrance® PDE5 Diabetic Staphylococcus Xeljanz ® Pain – tane
Slide 6: Delivering Novel & Differentiated Future Potential Products
Delivering Novel & Differentiated Future Potential Products Over the Next 4 Years: > 20 Potential Ph II/III Registration Study Starts > 15 Potential Approvals Oncology* CVMed Vaccines Inflammation Neuroscience Rare Disease Biosimilars & Pain Ibrance® ertugliflozin Prevenar® 13 Xeljanz® QD ALO-02 LAG
Slide 7: Delivering Novel & Differentiated Future Potential Products
Delivering Novel & Differentiated Future Potential Products 6 Near-Term Growth Platforms with Potential for Significant Market Opportunity Oncology CVMed Vaccines Inflammation Neuroscience Rare Disease Biosimilars & Pain Ibrance® bococizumab Prevenar ® 13 Xeljanz® LCM Neuro – rivipansel VOC trastuzu
Slide 8: Delivering Novel & Differentiated Future Potential Products
Delivering Novel & Differentiated Future Potential Products For Today’s Discussion Oncology CVMed Vaccines Inflammation Neuroscience Rare Disease Biosimilars & Pain Ibrance® bococizumab Prevenar® 13 Xeljanz® LCM Neuro – rivipansel VOC trastuzumab (palbociclib) (PCSK9) - Adult–CAPiTA Dopamine SCD Hyp
Slide 9: Pioneering Development Program - Ibrance (palbociclib)
Pioneering Development Program - Ibrance® (palbociclib) Opportunities in Other Potential Indications -- NSCLC, HNSCC, Melanoma, Pancreas Other Clinical tumor types Research Collaborations PENELOPE-B NSCLC, HNSCC, PEARL ER+ eBC Melanoma, (Stage Pancreas, PALOMA-2 ER+ eBC II / III) etc. Indication Lad
Slide 10: Pfizer and Merck KGaA Biopharma: A Great Match in Immuno-Oncology
Pfizer and Merck KGaA, Darmstadt, Germany, Biopharma A Great Match in Immuno-Oncology Wave 1 Wave 2 Single Agent Pfizer R&D Oncology avelumab* I/O Combinations (e.g., Sutent, Xalkori, Inlyta, (Anti PD-L1) Ibrance®/palbociclib) Lung avelumab* Immuno-oncology (e.g., 41-BB, OX40, CAR-T, Vaccines) Ovari
Slide 11: PF-06463922 Shows Promising Activity Against ALK-Positive Brain Metastases
PF-06463922 Shows Promising Activity Against ALK-Positive Brain Metastases Resistant to Xalkori™ 3-12-2014 6-17-2014 40-50% of Xalkori™ resistance in NSCLC developed through ALK mutations – Encouraging signs of clinical activity in ALKi-naïve and refractory patients – Early signs of clinical effic
Slide 12: bococizumab: A Differentiated Profile in the PCSK9 Class
bococizumab: A Differentiated Profile in the PCSK9 Class To Address >21M* Uncontrolled Patients in Major Markets % Change in LDL-C: Q14D Dosing Differentiation Unique clinical design Two CVOTs based on LDL-C criteria Enrollment of both 2⁰ and high risk 1⁰ prevention patients in CVOTs Down-titr
Slide 13: Potential First in Class Staphylococcus aureus Vaccine
Potential First in Class Staphylococcus aureus Vaccine Fast Track Designation Addressing a Serious, Life-threatening Disease OPA Measures S. aureus Killing Antibodies cLIA Measures Antibodies that Block Function of S. aureus Antigens CP5 100000 ClfA MntC 10000 10000 GMT GMT 10000 GMT 1000 1000 1000
Slide 14: Pfizer's World Leading JAK Franchise in Inflammation
Pfizer’s World Leading JAK Franchise in Inflammation Enabled by Strong Kinase Design Capabilities Leadership through Xeljanz® Selective JAKs Broad portfolio of differentiated JAKi’s Rheumatoid Arthritis Potential Indications Selective JAKs 37 ROW approvals (2014) Rheumatology JAK1 (Phase 2 Pso, SL
Slide 15: Expanding Inflammation Portfolio
Expanding Inflammation Portfolio Encouraging Ph2 Data in Ulcerative Colitis and Atopic Dermatitis Topical tofacitinib MAdCAM mAb Atopic Dermatitis Ulcerative Colitis mITT Population BASELINE 25% 23.6%* Moderate PGA EASI = 4.4 ISI = 9 20% 18.3%* 2% tofacitinib BID Remission Rate 15% 14.1%* 12.9% WEEK
Slide 16: Novel Mechanisms in Pain
Novel Mechanisms in Pain Anti-NGF mAb & Subtype Selective GABA A Enhancer tanezumab (anti-NGF) GABAA (Chronic Pain, Anxiety, Epilepsy) Consistent Reduction in Arthritis Pain 15 Saccadic Peak Velocity Decrease Infusion Infusion PD/efficacy marker 5 0 5 Baseline Pain Pain Reduction Coordination, balan
Slide 17: Rivipansel for Sickle Cell Crisis
Innovative Therapy for Sickle Cell Crisis Rivipansel for Sickle Cell Crisis pan-selectin inhibitor One of the largest opportunities in rare disease with 80,000 people in the Length of Hospital Stay (LOHS) U.S. alone* 1.0 0.9 Mean LOHS 5.2 days 0.8 (active) versus 7.3 days (placebo) – 32% reducti
Slide 18: Key Takeaways
Key Takeaways Multiple Strategic Growth Platforms and Acceleration Opportunities Advancing the First CDK 4/6 Drug as Breakthrough Therapy Growing Immuno-Oncology Pipeline – 5 I/O Assets in Clinic by Year-End Leveraging Differentiated Franchise Approach to PCSK9 Leading JAK Biology with New P
Pfizer — 33rd Annual J.P. Morgan Healthcare Conference (January 2015) on 6ix